Active, Not Recruiting
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
NCT03732677
- Conditions
- Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, +9 more
- Locations
-
- Research Site Birmingham, Alabama, United States
- Research Site Los Angeles, California, United States
- Research Site Palo Alto, California, United States
- Research Site New Haven, Connecticut, United States